Overview of conference on preclinical abuse liability testing: current methods and future challenges.

摘要

Preclinical abuse liability testing has long been an integral component of safety assessment in drag development, and members of CPDD have historically played a key role in developing experimental procedures and research strategies for investigating the abuse-related effects of new drugs. Results from these studies have been used by industry, academia and government to guide the selection of drugs for further development and by regulatory agencies to determine appropriate constraints on drug availability. In 2006, the European Medicines Agency (EMEA) published a document entitled "Guideline on the Non-Clinical Investigation of the Dependence Potential of Medicinal Products."